Hacettepe Üniversitesi Açık Erişim Sistemi (HÜAES)

  • HÜAES, Hacettepe Üniversitesi bünyesinde üretilen kitap, makale, tez, bildiri, rapor gibi tüm akademik kaynakları uluslararası standartlarda dijital ortamda depolar, etkisini artırmak için telif haklarına uygun olarak Açık Erişime sunar.
 

Communities in DSpace

Select a community to browse its collections.

Now showing 1 - 5 of 22

Recent Submissions

Thumbnail Image
Item
MEVALONAT KİNAZ EKSİKLİĞİ (MKE) HASTALARINDA PYRİN VE NLRP3 İNFLAMAZOMLARININ PRENİLASYON ÜZERİNE ETKİLERİNİN ARAŞTIRILMASI
(Sağlık Bilimleri Enstitüsü, 2026) Mehmet Emre Özkan; Tıbbi Biyoloji
Autoinflammatory diseases are rare and hereditary disorders characterized by excessive activation of the immune system as a result of pathological alterations in innate immunity, leading to recurrent inflammatory responses and periodic fever independent of infection. Familial Mediterranean Fever (FMF) is the most common autoinflammatory disease in Türkiye and arises from mutations in the MEFV gene encoding the pyrin protein. Another autoinflammatory disease, Mevalonate Kinase Deficiency (MKD), is an ultra-rare disorder caused by mutations in the MVK gene, which encodes the mevalonate kinase enzyme involved in the mevalonate pathway. It is thought that the autoinflammatory response observed in MKD patients results from a deficiency in prenylation. Prenylation is a post-translational modification observed in all eukaryotes and has been associated not only with autoinflammatory diseases but also with conditions such as cancer, Alzheimer’s disease, and progeria. This modification enables proteins to localize to and associate with cellular membranes and is believed to play a role in the suppression of the pyrin inflammasome through this function. Although previous studies have demonstrated that a deficiency in prenylation leads to inflammation, the effect of inflammation on prenylation itself has not yet been investigated. Within the scope of this thesis, pyrin and NLRP3 inflammasomes were stimulated in dermal fibroblast cells obtained from MKD patients, FMF patients, and healthy controls; in monocytes differentiated from induced pluripotent stem cells (iPSCs) derived from dermal fibroblasts of an FMF patient; and in primary monocytes isolated from the blood of MKD and FMF patients, in order to identify the predominant inflammasomes involved in these diseases. Subsequently, prenylation assays were performed in primary monocytes to examine the effects of the induced inflammatory response on prenylation. As a result of these experiments, it was observed that inflammation exacerbates prenylation deficiency in patients with MKD and FMF.
Thumbnail Image
Item
Dünyada Anne Ölümleri ve Postpartum Kanama
(Tıp Fakültesi, 2017) Boztas G; Gültekin M; Kadın Hastalıkları ve Doğum
No abstract available. This entry refers to a book chapter and no abstract is provided by the publisher.
Thumbnail Image
Item
FDA approves the first HPV self-collection solutions
(Tıp Fakültesi, 2024-11) Esra Bilir; Koray Görkem Saçıntı; Joanna Kacperczyk-Bartnik; Murat Gultekin; Kadın Hastalıkları ve Doğum
No abstract available. This publication is an editorial/short communication and does not include an abstract.
Thumbnail Image
Item
Criteria for second generation comparator tests in validation of novel HPV DNA tests for use in cervical cancer screening
(2024-09) Marc Arbyn; Kate Cuschieri; Jesper Bonde; Rob Schuurman; Clementina Cocuzza; Davy Vanden Broeck; Fang-Hui Zhao; Remila Rezhake; Murat Gultekin; Silvia de Sanjosé; Karen Canfell; David Hawkes; Marion Saville; Peter Hillemanns; Joakim Dillner; Johannes Berkhof; Jean-Luc Prétet; Tarik Gheit; Gary Clifford; Partha Basu; Maribel Almonte; Nicolas Wentzensen; Mario Poljak; Kadın Hastalıkları ve Doğum
While HC2 and GP5+/6+ PCR-EIA were pivotal in test validation of new HPV assays, they represent the first generation of comparator tests based upon technologies that are not in widespread use anymore. In the current guideline, criteria for second-generation comparator tests are presented that include more detailed resolution of HPV genotypes. Second-generation comparator tests should preferentially target only the 12 genotypes classified as carcinogenic (IARC-group I), and show consistent non-inferior sensitivity for CIN2+ and CIN3+ and specificity for ≤CIN1 compared to one of the first-generations comparators, in at least three validation studies using benchmarks of 0.95 for relative sensitivity and 0.98 for relative specificity. Validation should take into account used storage media and other sample handling procedures. Meta-analyses were conducted to identify the assays that fulfill these stringent criteria. Four tests fulfilled the new criteria: (1) RealTime High-Risk HPV Test (Abbott), (2) Cobas-4800 HPV test (Roche Molecular System), (3) Onclarity HPV Assay (BD Diagnostics), and (4) Anyplex II HPV HR Detection (Seegene), each evaluated in three to six studies. Whereas the four assays target 14 carcinogenic genotypes, the first two identify separately HPV16 and 18, the third assay identifies five types separately and the fourth identifies all the types separately.
Thumbnail Image
Item
Case studies on the progress of cervical cancer screening programs in Bhutan, India, and Türkiye
(2024-07) F Ricardo Burdier; Ana Bolio; Priya Abraham; Sharmila Pimple; Eduardo L Franco; Pempa Pempa; Mario Poljak; Murat Gultekin; Susanne K Kjær; Dur-E-Nayab Waheed; Alex Vorsters; Kadın Hastalıkları ve Doğum
International stakeholders gathered in New Delhi, India, in December 2022 to share experiences on human papillomaviruses (HPV) prevention and control strategies. As part of a supplementary publication from the meeting proceedings, this paper describes secondary HPV prevention strategies highlighting the varying degrees of progress and challenges through case studies from Bhutan, India, and Türkiye. India has implemented national screening guidelines, primarily using visual inspection with acetic acid (VIA), but achieving a low coverage rate of 1.9% (2022). In contrast, Bhutan and Türkiye have redesigned and established HPV-based cervical screening programs targeting women aged 30-65, achieving 77% (2022) and 95% (2019) coverage among women ever screened, respectively. Lessons learned include utilising patient health information management systems, analysing optimal context-specific HPV testing strategies and ensuring use and continuous supply of clinically validated HPV tests.